

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Hypertension	ATP-binding cassette sub-family C member 4 (ABCC4; MRP4)	<p>Studies in mice and in patient samples suggest inhibiting MRP4 could help treat pulmonary arterial hypertension (PAH). In lung samples isolated from PAH patients, MRP4 levels were greater than those in healthy controls. In a hypoxia-induced mouse model of PAH, <i>Mrp4</i> knockouts did not develop disease compared with wild-type mice, and a small molecule MRP inhibitor reversed development of PAH compared with saline. Next steps include identifying and developing a compound that specifically targets MRP4.</p> <p>SciBX 4(25); doi:10.1038/scibx.2011.712 Published online June 23, 2011</p>	Patented; available for licensing	<p>Hara, Y. <i>et al. J. Clin. Invest.</i>; published online June 13, 2011; doi:10.1172/JCI45023</p> <p>Contact: Jean-Sébastien Hulot, Pierre and Marie Curie University, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR956, Paris, France e-mail: jean-sebastien.hulot@psl.aphp.fr</p>